ArticlePreventive medicine reports2026
Determination of Human Papillomavirus prevalence in the female population from Zanjan, Iran.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Epidemiology of Human Papillomavirus in the Middle East and North Africa: A Review of Genotypic Prevalence, Vaccination Challenges, and Non-Cervical Clinical Outcomes.Diseases (Basel, Switzerland) · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Human papillomavirus (HPV) is the leading cause of cervical cancers and anogenital warts. Regional studies provide better insights to HPV prevalence and genotype trends in different populations. Methods: This cross-sectional study was done in Zanjan City, Iran from May 2022 to May 2023 for determination of specific high-risk HPV and low-risk types applying PCR in Pap smear samples collected from women aged from 24 to 60 years old. Results: 211 women were enrolled and the total HPV prevalence was 6.63% in this population. HPV16 and HPV11 accounted for 28.50% equally as the most prevalent genotypes in infected cases. Multiple HPV infections were seen 21.40% in whom HPV16 was dominant. There was a significant association between HPV positive status and cellular changes in Pap test and notably, of the cases with multiple HPV infections, HPV16 + 6 and HPV6 + 11 were detected in two cases with AS-CUS whereas HPV16 + 31 + 6 were detected in a case with HSIL. Conclusions: HPV prevalence has been estimated 6.63% with HPV16 and HPV11 dominancy in the present study. However, there is a high prevalence of multiple HPV infections in certain individuals. Therefore, it seems rational to provide an integrated approach, including vaccination, education, and access to preventative healthcare services.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.